Showing 4441-4450 of 5327 results for "".
- Mayo Clinic Data: Two Forms of Nonmelanoma Skin Cancer on the Risehttps://practicaldermatology.com/news/mayo-clinic-data-two-forms-of-nonmelanoma-skin-cancer-on-the-rise/2458167/Two types of non-melanoma skin cancer (NMSC) have increased significantly in recent years, according to a new report in the June 2017 issue of Mayo Clinic Proceedings. Specificall
- First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for EBShttps://practicaldermatology.com/news/first-patient-enrolled-in-delivers-study-of-diacerein-1-ointment-for-ebs/2458168/The first patient has enrolled in Castle Creek Pharmaceuticals (CCP) Phase 2/3 DELIVERS clinical trial evaluating the safety and efficacy of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bull
- Luminora Launches New UPF Sunwear Linehttps://practicaldermatology.com/news/luminora-launches-new-upf-sunwear-line/2458169/Founded by skin cancer surgeon, Dr. Ali Hendi, and his designer wife, Azi Hendi, the Spring/Summer 2017 collection from Luminora launched in May with 12 foundational pieces priced from $60 to $485. Luminora™ is a new
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- Largest Psoriasis Meta-Analysis to Date Yields New Genetic Clueshttps://practicaldermatology.com/news/largest-psoriasis-meta-analysis-to-date-yields-new-genetic-clues/2458176/A new meta -analysis identifies 16 additional genetic markers that may help researchers get closer to understanding how — and why — psoriasis develops. University of Michigan researchers, working with partners across the globe, published the work in
- Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADEhttps://practicaldermatology.com/news/kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade/2458177/Emmy and Tony award-winning actress and singer Kristin Chenoweth is kicking off Allergan’s Rhofade "Less Red, More You" campaign. Chenoweth, who has rosacea, will begin a nationwide conversation about the condition while raising a
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- RCM Imaging of Skin Granted Reimbursement Codes by CMS; Wider Adoption Likelyhttps://practicaldermatology.com/news/rcm-imaging-of-skin-granted-reimbursement-codes-by-cms/2458187/After more than two decades of effort, reflectance confocal microscopy (RCM) imaging of skin has been granted reimbursement codes by the US Centers for Medicare and Medicaid Services. A report in Lasers in Sur
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to